Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. - Wikidata - awgldk - TriplyDB

Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.

Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.

http://www.wikidata.org/entity/Q34324771

about

A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure State of the Art: Newer biomarkers in heart failure B-type natriuretic peptide-guided treatment for heart failure.Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence.Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure.Personalized treatment of heart failure with biomarker guidance using a novel disease severity score.The vulnerable phase after hospitalization for heart failure.Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.NT-proBNP and Echocardiographic Parameters for Prediction of Cardiovascular Outcomes in Patients with CKD Stages G2-G4.The Current and Potential Clinical Relevance of Heart Failure Biomarkers.Using biomarkers to guide heart failure management.Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.Resetting the neurohormonal balance in heart failure (HF): the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF Remote Monitoring to Reduce Heart Failure Readmissions.Can Natriuretic Peptides be Used to Guide Therapy?Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity.Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).Association between cardiac, renal, and hepatic biomarkers and outcomes in patients with acute heart failure.Heart failure with reduced ejection fraction.Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure.Association between Survival Time and Changes in NT-proBNP in Cats Treated for Congestive Heart Failure.Natriuretic peptide and cardiovascular risk: is it about "U"?Contemporary roles of registries in clinical cardiology: when do we need randomized trials?Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial.Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study.Novel Wearable Seismocardiography and Machine Learning Algorithms Can Assess Clinical Status of Heart Failure Patients.MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations.Dynamic Changes in High-Sensitivity Cardiac Troponin I Are Associated with Dynamic Changes in Sum Absolute QRST Integral on Surface Electrocardiogram in Acute Decompensated Heart Failure.Natriuretic Peptides in Older Patients With Heart Failure: A Look Into the Seeds of Time.Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.Novel concept to guide systolic heart failure medication by repeated biomarker testing-results from TIME-CHF in context of predictive, preventive, and personalized medicine.Continuous biomarker monitoring by particle mobility sensing with single molecule resolution.Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease

P2860

Q26770151-843E39BB-BF54-45BC-B842-24031CBA486E Q27027899-38060727-4A0E-401A-8148-811000091E58 Q30238936-7CD313B0-E439-46D6-B92A-BA25C39EEFB4 Q33862358-415B0CC4-BD08-4876-94D1-F446C2D137FE Q37576886-B5E12466-ECC7-4988-AF29-05C642AA91AD Q37699042-F50798CE-3C0B-49FA-A499-AEE1F3772F22 Q38349760-A601F9F5-2CEF-4E23-9B4E-3400C668EAAB Q38371833-AF923F40-862F-4607-8EE4-F2DB55BC49AB Q38378152-62EB44C8-356A-43FE-8A73-C945319F19E0 Q38568205-E1D85831-36AC-450A-898E-2DCC14C16065 Q38613842-CA23B093-5C3B-4B68-A849-66E9DCEDEAC2 Q38754215-3BB26B7D-4ADA-41B6-8897-7C98A6F1B6DC Q38756838-474EC97B-4C31-4824-8D38-97EA4DEEBB46 Q38854043-68C05C4E-ADED-4329-A8AA-20886E09A5DF Q38953625-F857D21A-9344-44A2-8974-9731DFD64409 Q38967512-2576B394-536D-4C0D-AE74-4A0F84EAA175 Q38978044-89B326EB-3C22-4907-9263-9F5026E64C67 Q39059489-CD14DC85-C8B0-4A80-8D7B-0A3464FD0D54 Q39689820-9AC77552-9888-479E-BBF5-4E963792E055 Q40081533-83732193-712A-4BF0-9D1B-9A17E91F718F Q41381124-D73EDFA4-FAA6-4C5F-B6F5-3917E1C14204 Q42260678-32352DD7-9472-4149-B7F0-618A7E345375 Q43228079-6419F08D-83BA-4B7D-B3A7-DCD10B393CBE Q45894982-35645E80-919A-4D53-8F2A-2FE3D19F521B Q46005004-150B78E5-B225-4299-AFFE-45949B969BC1 Q47191187-4B2F8426-FBFC-46F2-ABE4-F2C49F192A8A Q47564062-70C13C01-0E4B-443C-AB8C-ED7DE545561A Q47644374-8AA11016-35A7-4316-B1C0-02D597A14760 Q47855200-034E54F5-F93E-4BC9-83C8-EC93A7D99B0F Q50016205-28C65F06-0458-4F12-A3AD-91CB93F58CC9 Q50890696-C25B4863-9B78-4413-88CF-61C9BADD6530 Q50905395-9E639BB0-24C9-472D-84D4-3A73F08EE323 Q53121367-847949EE-2BF0-4F74-91D5-94E6CD88B4B4 Q55409538-ED014076-7924-4191-BCDD-70914B976955 Q55452015-1871477D-2289-4C6E-A5D1-07165E484D35 Q58738210-0F446964-7CAC-457F-B930-FD2B5498FF1D

P2860

Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.

http://www.wikidata.org/entity/Q34324771

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@ast

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@en

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@nl

type

label

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@ast

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@en

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@nl

prefLabel

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@ast

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@en

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@nl

P1433

Q34324771-F2ECDA5C-9652-48BC-A03C-0DDFBB76FEC5

P1476

Q34324771-38C709B7-F2D8-4D26-A352-E9B334B907D2

P2093

Q34324771-1377ED59-4E0A-4749-88AA-9A95BD39DDCF

Q34324771-23149759-3D55-405A-B3C3-CB5319B6928E

Q34324771-233420DF-7A21-4FC9-8BC4-1A66BF80906B

Q34324771-312FFCF3-F760-495A-9418-86027F88BCA6

Q34324771-425F2F5C-9937-41DF-B1A3-D94635B94E1C

Q34324771-637E2149-5C50-4C5C-812E-009C7E7FB090

Q34324771-7B4829EF-24F3-4B6D-9D43-F0D09F9F0880

Q34324771-9E33F38B-6E0F-48EB-BC30-DCCF4913D484

Q34324771-A45EF4B1-7482-46C6-A5ED-87FD1E934E2E

Q34324771-BCA6909F-1A96-4711-A83F-95FA10DAF1AA

P2860

Q34324771-0A4F1A60-B664-4786-8817-4C75DA1BD3A6

Q34324771-0A72DB06-D312-4370-A733-19C13A2D06A7

Q34324771-168E47F0-1235-40BB-823C-8A888CD14D56

Q34324771-19285CA3-423E-4B68-843B-646C2C40B933

Q34324771-19EAB629-FD71-4C4F-8029-F4BA0E4771ED

Q34324771-1D38F913-C3D1-4CBD-A00F-DCA20659E13D

Q34324771-20451309-F7CB-436D-9532-A9B38E432A45

Q34324771-2E7A7C7C-20C6-4F31-9091-A3D745E549FC

Q34324771-31C70BC9-28ED-4C35-BF98-5C06A37557FE

Q34324771-3CCCDA04-B8F3-4D2D-8824-406305CB8940

P304

Q34324771-B2190B2F-7E27-4498-97EB-3062F64BD196

P31

Q34324771-106DD9D4-8F0A-43F3-80A6-9FE5ECB793BE

P356

Q34324771-13083D5E-5976-4708-BE92-62E0B5847E77

P433

Q34324771-D5FE412B-4A77-4770-911B-27FED9C6E466

P478

Q34324771-47681118-2E4D-4964-A4ED-C45A63002F2F

P50

Q34324771-146A24F6-3D82-42E1-A16A-D40C21A4239F

Q34324771-2348958E-06F0-4FB8-A3D2-9A33BBA58F08

Q34324771-6916452E-10DA-481F-8708-FAEE71D21B4A

Q34324771-9EC7E438-D2F6-463C-AFF0-C957F867C44B

Q34324771-A602CCDF-5D83-4B97-9F96-F56122008FC3

P577

Q34324771-F3778094-8144-4C78-9EF2-43D2D7A95A22

P698

Q34324771-48C4A05F-6EBB-4C6E-9044-F10A3C862E06

P921

Q34324771-A2596F6F-E2A3-42CA-A288-FB7EB8929C6B

P932

Q34324771-4AF75175-F3A4-41B9-87BF-39A58E1D5B7F

P356

J.JCHF.2014.05.007

P1433

JACC: Heart Failure

P1476

Rationale and design of the GU ...... ed Treatment in Heart Failure.

@en

P2093

David J Whellan

http://www.w3.org/2001/XMLSchema#string

Eric S Leifer

http://www.w3.org/2001/XMLSchema#string

G Michael Felker

http://www.w3.org/2001/XMLSchema#string

Gayle Paynter

http://www.w3.org/2001/XMLSchema#string

Ileana L Piña

http://www.w3.org/2001/XMLSchema#string

Kirkwood F Adams

http://www.w3.org/2001/XMLSchema#string

Lawton S Cooper

http://www.w3.org/2001/XMLSchema#string

Mona Fiuzat

http://www.w3.org/2001/XMLSchema#string

Nancy Houston-Miller

http://www.w3.org/2001/XMLSchema#string

Patrice Desvigne-Nickens

http://www.w3.org/2001/XMLSchema#string

P2860

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design

The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use

The underutilization of cardiac medications of proven benefit, 1990 to 2002

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.

The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Barriers to accurate diagnosis and effective management of heart failure in primary care: qualitative study.

Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials

Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in

P304

457-465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCHF.2014.05.007

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Justin A. Ezekowitz

Kevin J Anstrom

James L Januzzi

Christopher M O'Connor

P577

2014-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25194287

http://www.w3.org/2001/XMLSchema#string

P921

P932

4194159

http://www.w3.org/2001/XMLSchema#string